PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23784744-0	2013	Naproxen and cromolyn as new glycogen synthase kinase 3beta inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation.	Cromolyn Sodium	13-21	glycogen synthase kinase 3 beta	Mus musculus	29-59	
23784744-1	2013	Naproxen and cromolyn were investigated as new inhibitors of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain their hypoglycemic properties.	Cromolyn Sodium	13-21	glycogen synthase kinase 3 beta	Mus musculus	61-91	
23784744-1	2013	Naproxen and cromolyn were investigated as new inhibitors of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain their hypoglycemic properties.	Cromolyn Sodium	13-21	glycogen synthase kinase 3 beta	Mus musculus	93-102	
23784744-3	2013	Both drugs not only were optimally fitted within a GSK-3beta binding pocket via several attractive interactions with key amino acids but also exhibited potent in vitro enzymatic inhibitory activities of IC50 1.5 and 2.0 microM for naproxen and cromolyn, respectively.	Cromolyn Sodium	244-252	glycogen synthase kinase 3 beta	Mus musculus	51-60	
23784744-6	2013	It can be concluded that naproxen and cromolyn are novel GSK-3beta inhibitors and can help in management of diabetes and obesity.	Cromolyn Sodium	38-46	glycogen synthase kinase 3 beta	Mus musculus	57-66